12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Company News  |  Deals

Adocia, Eli Lilly deal

The companies mutually terminated a December 2011 deal to develop and commercialize a version of Lilly's Humalog insulin lispro that uses Adocia's BioChaperone polymer technology. Adocia, which retains IP developed under...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >